Abstract：
:THE ROLE OF RUXOLITINIB IN THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS: The discovery of the JAK2V617F mutation in 2005, present in 95% of polycythemia vera (PV) and in 55% of myelofibrosis (MF) patients, opened the way for a new era of targeted therapies for myeloproliferative neoplasms. Ruxolitinib was the first-in-class Janus Kinase (JAK) inhibitor approved for the management of these diseases. In PV patients, conventional treatment strategies including aspirin, phlebotomy, cytoreductive agents such as hydroxyurea and interferon, clearly provide clinical benefits. However, some patients develop resistance or intolerance to these treatments. Ruxolitinib has been approved for PV patients who are resistant to or intolerant of hydroxyurea, based on the results of the phase 3 RESPONSE study. This study showed that ruxolitinib improves hematocrit control, reduces splenomegaly, and ameliorate disease-related symptoms as compared with best available therapy. In MF patients, the only curative treatment is allogeneic stem cell transplantation, but it remains restricted to a limited group of patients with poor prognosis and who are eligible for such procedure associated with non-negligible transplant-related mortality. Other treatments are palliative and unlikely to prolong survival. Ruxolitinib has been approved in the United States for MF patients with intermediate or high-risk disease, and in Europe for disease-related splenomegaly or symptoms in adults with MF, based on phase 3 COMFORT-I and COMFORT-II studies. These studies showed that ruxolitinib was able to reduce splenomegaly, ameliorate symptoms, and improve survival. However, the journey is not finished yet since there are still important unmet needs for MF patients, including improvement in cytopenias, and significant modification of disease natural history.
journal_name
Bull Cancerjournal_title
Bulletin du cancerauthors
Soret J,Kiladjian JJdoi
10.1016/S0007-4551(16)30143-6subject
Has Abstractpub_date
2016-06-01 00:00:00pages
S29-38issue
6 Suppl 1eissn
0007-4551issn
1769-6917pii
S0007-4551(16)30143-6journal_volume
103pub_type
杂志文章,评审abstract：:EXPRESSION III was designed to evaluate the information, needs and expectations of patients with ovarian cancer in different European countries. This abstract focuses on specific results from French OC patients. Two hundred and fifty-seven patients filled a 27-item questionnaire during a medical visit. Median age rang...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：10.1016/j.bulcan.2014.09.004
更新日期：2015-03-01 00:00:00
abstract：:Thymidine kinase (TK) was assayed in the cytosol of 210 primary breast cancers to assess its predictive value for response to first line chemotherapy and hormonotherapy. We performed correlations between TK and the other prognosis factors of breast cancer. TK activity is correlated with SBR grading and estrogen recept...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：
更新日期：1992-01-01 00:00:00
abstract：:Two hundred and twenty-three patients with disseminated breast cancer entered in a randomized trial: Group I: 130 patients were given a monthly 5 day- course of a cytotoxic chemotherapy protocol including Adriamycine, Vincristine, Cyclophosphamide, 5 Fluoro-uracile (A.V.L.F.); Group II: 93 patients were given alternat...
journal_title：Bulletin du cancer
pub_type： 临床试验,杂志文章,随机对照试验
doi：
更新日期：1984-01-01 00:00:00
abstract：:mdm2 (mouse double minute) protein seems lead to p53 inactivation and therefore might potentially play a role in carcinogenesis. We have studied mdm2 gene amplification from 239 primary breast cancer tissues. mdm2 gene was amplified in 10% of cases (25/239). mdm2 amplification was associated with c-erbB2 amplification...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：
更新日期：1994-07-01 00:00:00
abstract：:Robotic assisted surgery is a new field of developing program for many specialties. As to head and neck oncology, the new procedure potentially offers alternatives to conventional surgery with decreased morbidity. The aim of this article is a description of the state of the art via a review of the literature. We empha...
journal_title：Bulletin du cancer
pub_type： 杂志文章,评审
doi：10.1684/bdc.2009.1022
更新日期：2010-01-01 00:00:00
abstract：:To have a better understanding of the poor participation rate among general practitioners (GPs) in cervical cancer screening, we have conducted a survey in the department of Bas-Rhin on a small sample of GPs. This helped to explain how they perceived this technical act, the problems or barriers related to it: rate, fu...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：
更新日期：1994-04-01 00:00:00
abstract：:Angiopoietin-2 is a new member of the family of the ligands of Tek (Tie2), a transmembrane receptor with tyrosine kinase activity which is specifically expressed in endothelial cells during angiogenesis. Several lines of evidence indicate that angiopoietin-1 is involved in pericyte recruitment by endothelial cells and...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：
更新日期：1997-11-01 00:00:00
abstract：BACKGROUND:The standard treatment in first line of advanced or metastatic urothelial bladder cancer (MBC) is the association of Gemcitabine and Cisplatin (GC). Avelumab, an anti-PD-L1 agent, has recently demonstrated efficacy. The objective is to evaluate the combination of these 3 agents. METHODS:This phase II random...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：10.1016/S0007-4551(20)30280-0
更新日期：2020-06-01 00:00:00
abstract：:Brain metastases management is still controversial even though many trials are trying to define the respective roles of neurosurgery, whole-brain radiotherapy, single-dose stereotactic radiotherapy and fractionated stereotactic radiotherapy. In this article, we review data from trials that examine the role of radiosur...
journal_title：Bulletin du cancer
pub_type： 杂志文章,评审
doi：10.1684/bdc.2012.1683
更新日期：2013-01-01 00:00:00
abstract：:This survey, conducted in region Rhône-Alpes (France), aims to assess some data in thoracic oncology practice including availability of specialized equipments. This study is based on a questionnaire mailed to oncologists and pulmonologists in the region. Of 401 questionnaires, the response rate was 56%. Responses of 7...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：10.1684/bdc.2011.1366
更新日期：2011-06-09 00:00:00
abstract：:Enzalutamide (MDV3100) is a non-steroidal antiandrogen of second generation that has shown efficacy in metastatic castration-resistant prostate cancer (mCRPC). The study AFFIRM demonstrated a statistically significant increase in overall survival among patients who have progressed following a docetaxel chemotherapy. B...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：10.1684/bdc.2013.1880
更新日期：2014-01-01 00:00:00
abstract：:Infectious complications associated with granulocytopenia during the treatment of poor risk or relapsed germ cell tumors were studied in order to assess the frequency, morbidity and characteristics of these complications. Thirty-three cases were investigated at the Institut Gustave-Roussy; 63 episodes of granulocytope...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：
更新日期：1992-01-01 00:00:00
abstract：:This year, the innovations were numerous in sarcomas. Important progress were accomplished in the search for predictive factors which make it possible to propose to the patient a personalized treatment with the therapeutic ones reduced in the event of good prognosis or on the contrary aggressive steps in the event of ...
journal_title：Bulletin du cancer
pub_type： 杂志文章,评审
doi：
更新日期：2006-01-01 00:00:00
abstract：:There are very few active drugs in the treatment of metastatic gastric carcinoma. Among new drugs, docetaxel has shown one of the most important activity. With precise evaluation of objective response, this drug has demonstrated a 20% response rate in monotherapy. The favorable toxicity profile of this compound allowe...
journal_title：Bulletin du cancer
pub_type： 杂志文章,评审
doi：
更新日期：2004-03-01 00:00:00
abstract：:The radiobiological properties of the hadrons (neutrons, protons, carbon ions) led to their therapeutic use in sarcomas, as a referent therapy or as an alternative to photon therapy. An extensive review of the literature has been conducted to assess the present indications and the perspectives for hadrontherapy. Compa...
journal_title：Bulletin du cancer
pub_type： 杂志文章,评审
doi：10.1684/bdc.2010.1125
更新日期：2010-06-01 00:00:00
abstract：:Despite development and widespread of PSA, current tools evaluating prostate cancer still give inconsistent or insufficiently relevant results. As encouraging data raised from circulating tumor cells detection in colon or breast cancer, they were evaluated as a surrogate prostate cancer biomarker. Tumor cells need to ...
journal_title：Bulletin du cancer
pub_type： 杂志文章,评审
doi：10.1684/bdc.2012.1565
更新日期：2012-07-01 00:00:00
abstract：:The first study evaluating directly by the referring physician the clinical impact of [18F]-FDG-PET on modification of patient's management was performed only recently in California by means of a questionnaire. We have used the same methodology to evaluate this clinical impact during the opening year of our PET centre...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：
更新日期：2002-03-01 00:00:00
abstract：:We have examined the effect of cyclosporin A on transport processes (uptake, efflux, binding) of mitoxantrone in isolated rat liver cells. Accumulation and binding of mitoxantrone was rapid with or without cyclosporin A. The initial uptake was linear over a wide concentration range (1 to 1000 microM). For the first 10...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：
更新日期：1994-05-01 00:00:00
abstract：:Important progress have been recently achieved in the management of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). Prognostic factors are now better defined in HD thanks to new biologic and radiologic information which complete old and relevant clinical factors. These parameters are expected to improve decis...
journal_title：Bulletin du cancer
pub_type： 杂志文章,评审
doi：
更新日期：2002-01-01 00:00:00
abstract：FOCAL TREATMENT AND SYSTEMIC THERAPY IN METASTATIC KIDNEY CANCER:COMPLEMENTARY APPROACHES: To treat metastatic renal cell carcinoma, therapies used are with an oral intake, for the vast majority, and have many side effects that may compromise observance. Strategies of drug holiday have been studied and, in case of an i...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：10.1016/S0007-4551(18)30376-X
更新日期：2018-12-01 00:00:00
abstract：:Colorectal cancer occurs after the age of 75 in 50% of the case, but elderly patients are under-treated and far from an optimal management of their disease. Principles of colorectal cancer management after the age of 75 are theoretically the same than for younger patients, but physiological age, comorbidities and pati...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：10.1684/bdc.2007.0545
更新日期：2008-05-28 00:00:00
abstract：:Between 1964 and 1978, 21 patients with locally extensive soft tissue sarcoma received intal-arterial regional chemotherapy (IAC), combined with radiotherapy. Some patients were also submitted to conservative surgery. Although there were three serious accidents, one of which was lethal, the tolerance was considered ac...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：
更新日期：1980-01-01 00:00:00
abstract：:Unusual aspect of the development of oxaliplatin was that substantial evidence of its activity was gathered when used in combination with protracted infusion of 5FU combined with leucovorin, preceeding the formal demonstration of its single activity in this disease. Phase II trials in previously treated patients by 5F...
journal_title：Bulletin du cancer
pub_type： 杂志文章,评审
doi：
更新日期：2001-08-01 00:00:00
abstract：:Despite its status as a rare disease, the incidence of the squamous cell carcinoma of the anus (SCCA) is surging, especially in its metastatic form. In addition, the prognosis of initially localized diseases has not substantially changed since the 1970s with a recurrence rate of between 25-40 % after the chemoradiothe...
journal_title：Bulletin du cancer
pub_type： 杂志文章,评审
doi：10.1016/j.bulcan.2020.12.001
更新日期：2021-01-01 00:00:00
abstract：:Protein phosphorylation is a fundamental post-translational modification. It regulates a large number of critical cellular processes (differentiation, division, proliferation, apoptosis). Cell division is a process including a series of phases by which a parent cell divides into two daughter cells. The cells enter the...
journal_title：Bulletin du cancer
pub_type： 杂志文章,评审
doi：10.1684/bdc.2011.1383
更新日期：2012-02-01 00:00:00
abstract：:This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens. Patient samples were stained with antibodies directed against total beta tubulin, classes I, II and III beta tubulin isotyp...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：
更新日期：2005-02-01 00:00:00
abstract：:The serious digestive side effects of the selective inhibitors the inducible cyclooxygenase-2 are reduced by 60% as compared to the nonselective non-steroidal anti-inflammatory drugs. The main risk factors associated with gastro-intestinal ulcers caused by the latter were found also with the selective inhibitors taken...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：
更新日期：2004-05-01 00:00:00
abstract：AIM:Harvesting of the "sentinel lymph node" (SLN) as identified by lymphoscintigraphy (LSG) is becoming increasingly important in the staging of patients with malignant melanoma. The purpose of the current study was to determine whether the appearance time of the LSG had a prognostic value in predicting metastasis diss...
journal_title：Bulletin du cancer
pub_type： 杂志文章
doi：
更新日期：2004-07-01 00:00:00
abstract：:Angiogenin is one of the most potent inducers of neovascularization in experimental models in vivo. Angiogenin is normally present in plasma but overexpressed in cancer patients. The possible involvement of angiogenin in the development of cancer is suggested by its overexpression in patients with a variety of tumours...
journal_title：Bulletin du cancer
pub_type： 杂志文章,评审
doi：
更新日期：2001-08-01 00:00:00
abstract：:Whereas it has been proposed almost one century ago, brachytherapy for prostate cancer has only recently emerged, especially thanks to endorectal echography, allowing to visualize seed implantation, to the development of seeds for permanent delivery and of micro-sources for high-dose rate delivery, and also to the dev...
journal_title：Bulletin du cancer
pub_type： 杂志文章,评审
doi：
更新日期：2006-08-01 00:00:00
